Literature DB >> 31566308

Understanding Progressive Fibrosing Interstitial Lung Disease through Therapeutic Trials.

Hilary J Goldberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31566308     DOI： 10.1056/NEJMe1911794

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don't.

Authors:  Giacomo Sgalla; Pier-Valerio Mari; Luca Richeldi
Journal:  Ann Transl Med       Date:  2020-12

Review 2.  The role of antifibrotics in the treatment of rheumatoid arthritis-associated interstitial lung disease.

Authors:  Minrui Liang; Eric L Matteson; Andy Abril; Jörg H W Distler
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-02-15       Impact factor: 5.346

Review 3.  Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme.

Authors:  Claudia Valenzuela; Sebastiano Emanuele Torrisi; Nicolas Kahn; Manuel Quaresma; Susanne Stowasser; Michael Kreuter
Journal:  Respir Res       Date:  2020-01-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.